V. Cogliano, Y. Grosse, R. Baan, K. Straif, and B. Secretan, Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment, The Lancet Oncology, vol.6, issue.8, pp.552-553, 2005.
DOI : 10.1016/S1470-2045(05)70273-4

F. Stanczyk, All progestins are not created equal, Steroids, vol.68, issue.10-13, pp.879-890, 2003.
DOI : 10.1016/j.steroids.2003.08.003

J. Pasqualini, J. Paris, R. Sitruk-ware, G. Chetrite, and J. Botella, Progestins and breast cancer, The Journal of Steroid Biochemistry and Molecular Biology, vol.65, issue.1-6, pp.225-235, 1998.
DOI : 10.1016/S0960-0760(98)00028-4

S. Lee, R. Ross, and M. Pike, An overview of menopausal oestrogen???progestin hormone therapy and breast cancer risk, British Journal of Cancer, vol.151, issue.11, pp.2049-2058, 2005.
DOI : 10.1016/S0029-7844(02)02502-4

C. Campagnoli, C. Abba, S. Ambroggio, and C. Peris, Pregnancy, progesterone and progestins in relation to breast cancer risk, The Journal of Steroid Biochemistry and Molecular Biology, vol.97, issue.5, pp.441-450, 2005.
DOI : 10.1016/j.jsbmb.2005.08.015

M. Stefanick, G. Anderson, and K. Margolis, Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy, JAMA, vol.295, issue.14, pp.1647-1657, 2006.
DOI : 10.1001/jama.295.14.1647

C. Magnusson, J. Baron, N. Correia, R. Bergstrom, H. Adami et al., Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy, International Journal of Cancer, vol.4, issue.3, pp.339-344, 1999.
DOI : 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6

P. Newcomb, L. Titus-ernstoff, and K. Egan, Postmenopausal estrogen and progestin use in relation to breast cancer risk, Cancer Epidemiol Biomarkers Prev, vol.11, pp.593-600, 2002.

V. Beral, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-427, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

C. Stahlberg, A. Pedersen, and E. Lynge, Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe, International Journal of Cancer, vol.76, issue.5, pp.721-727, 2004.
DOI : 10.1002/ijc.20016

K. Bakken, E. Alsaker, A. Eggen, and E. Lund, Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian Women and Cancer study, International Journal of Cancer, vol.112, issue.1, pp.130-134, 2004.
DOI : 10.1002/ijc.20389

M. Ewertz, L. Mellemkjaer, and A. Poulsen, Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study, British Journal of Cancer, vol.288, issue.7, pp.1293-1297, 2005.
DOI : 10.1002/ijc.20016

S. Lee, L. Kolonel, L. Wilkens, P. Wan, B. Henderson et al., Postmenopausal hormone therapy and breast cancer risk: The multiethnic cohort, International Journal of Cancer, vol.289, issue.5, pp.1285-1291, 2006.
DOI : 10.1002/ijc.21481

M. Hickey, S. Davis, and D. Sturdee, Treatment of menopausal symptoms: what shall we do now?, The Lancet, vol.366, issue.9483, pp.409-421, 2005.
DOI : 10.1016/S0140-6736(05)66519-1

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-chapelon, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, International Journal of Cancer, vol.158, issue.3, pp.448-454, 2005.
DOI : 10.1002/ijc.20710
URL : https://hal.archives-ouvertes.fr/inserm-00129104

E. Riboli, K. Hunt, and N. Slimani, European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection, Public Health Nutrition, vol.59, issue.6b, pp.1113-1124, 2002.
DOI : 10.1093/ije/26.suppl_1.S1

N. Weiss and M. Rossing, Healthy screenee bias in epidemiologic studies of cancer incidence, Epidemiology, vol.7, pp.319-322, 1996.

R. Santen, Risk of breast cancer with progestins: critical assessment of current data, Steroids, vol.68, issue.10-13, pp.953-964, 2003.
DOI : 10.1016/S0039-128X(03)00138-7

B. De-lignieres, Effects of progestogens on the postmenopausal breast, Climacteric, vol.72, issue.3, pp.229-235, 2002.
DOI : 10.1016/S0029-7844(97)00212-3

J. Graham and C. Clarke, Physiological Action of Progesterone in Target Tissues, Endocrine Reviews, vol.18, issue.4, pp.502-519, 1997.
DOI : 10.1210/er.18.4.502

C. Wood, T. Register, C. Lees, H. Chen, S. Kimrey et al., Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys, Breast Cancer Research and Treatment, vol.280, issue.2, pp.125-134, 2007.
DOI : 10.1007/s10549-006-9276-y

P. Muti, M. Stanulla, and A. Micheli, Markers of insulin resistance and sex steroid hormone activity in relation to breast cancer risk: a prospective analysis of abdominal adiposity, sebum production, and hirsutism (Italy), Cancer Causes and Control, vol.11, issue.8, pp.721-730, 2000.
DOI : 10.1023/A:1008966623901

C. Li, Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist, Maturitas, vol.49, issue.1, pp.44-50, 2004.
DOI : 10.1016/j.maturitas.2004.05.015

W. Ray, Evaluating Medication Effects Outside of Clinical Trials: New-User Designs, American Journal of Epidemiology, vol.158, issue.9, pp.915-920, 2003.
DOI : 10.1093/aje/kwg231

G. Greendale, B. Reboussin, S. Slone, C. Wasilauskas, M. Pike et al., Postmenopausal Hormone Therapy and Change in Mammographic Density, JNCI Journal of the National Cancer Institute, vol.95, issue.1, pp.30-37, 2003.
DOI : 10.1093/jnci/95.1.30